Morphoproteomic-guided host-directed therapy for tuberculosis

Frontiers in Immunology

Volumn 8, Issue FEB, 2017, Pages

  Brown, Robert E ^a   Hunter, Robert L ^a   Hwang, Shen An ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

COX 2; Host directed therapy; Morphoproteomics; MTOR; Tuberculosis

Indexed keywords

ANTIDIABETIC AGENT; CELECOXIB; CYCLOOXYGENASE 2; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; PROGRAMMED DEATH 1 LIGAND 1; PROSTAGLANDIN E2; SOMATOMEDIN C;

APOPTOSIS; ARTICLE; ASPIRATION PNEUMONIA; BACTERIAL LOAD; GENE OVEREXPRESSION; HOST DIRECTED THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; LUNG PARENCHYMA; LUNG TUBERCULOSIS; MACROPHAGE ACTIVATION; METABOLISM; MICROENVIRONMENT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PROTEIN EXPRESSION; PROTEOMICS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION;

EID: 85014414926     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00078     Document Type: Article

References (78)

1. Chaves AS, Rodrigues MF, Mattos AM, Teixeira HC. Challenging Mycobacterium tuberculosis dormancy mechanisms and their immunodiagnostic potential. Braz J Infect Dis (2015) 19:636-42. doi: 10.1016/j.bjid.2015.08.004
2. Saunders BM, Britton WJ. Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol (2007) 85:103-11. doi:10.1038/sj.icb.7100027
3. Vukmanovic-Stejic M, Reed JR, Lacy KE, Rustin MH, Akbar AN. Mantoux test as a model for a secondary immune response in humans. Immunol Lett (2006) 107:93-101. doi:10.1016/j.imlet.2006.08.002
4. Collins FM. Antituberculous immunity: new solutions to an old problem. Rev Infect Dis (1991) 13:940-50. doi:10.1093/clinids/13.5.940
5. Khan N, Vidyarthi A, Javed S, Agrewala JN. Innate immunity holding the flanks until reinforced by adaptive immunity against Mycobacterium tuberculosis infection. Front Microbiol (2016) 7:328. doi:10.3389/fmicb.2016.00328
6. Korb VC, Chuturgoon AA, Moodley D. Mycobacterium tuberculosis: manipulator of protective immunity. Int J Mol Sci (2016) 17:131. doi:10.3390/ijms17030131
7. Baxter D. Active and passive immunization for cancer. Hum Vaccin Immunother (2014) 10:2123-9. doi:10.4161/hv.29604
8. Hay MP, Hicks KO, Wang J. Hypoxia-directed drug strategies to target the tumor microenvironment. Adv Exp Med Biol (2014) 772:111-45. doi:10.1007/978-1-4614-5915-6_6
9. Jager K, Walter M. Therapeutic targeting of telomerase. Genes (Basel) (2016) 7:39-64. doi:10.3390/genes7070039.
10. Lechner MG, Russell SM, Bass RS, Epstein AL. Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy (2011) 3:1317-40. doi:10.2217/imt.11.115
11. Savas P, Hughes B, Solomon B. Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer. J Thorac Dis (2013) 5(Suppl 5):S579-92. doi:10.3978/j.issn.2072-1439.2013.08.52
12. Weitzenfeld P, Ben-Baruch A. The chemokine system, and its CCR5 and CXCR4 receptors, as potential targets for personalized therapy in cancer. Cancer Lett (2014) 352:36-53. doi:10.1016/j.canlet.2013.10.006
13. Chun J, Rosen H. Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases. Curr Pharm Des (2006) 12:161-71. doi:10.2174/138161206775193109
14. Dunne PJ, Fletcher JM. Recent advances in regulatory T cell therapy of autoimmunity, graft rejection and cancer. Recent Pat Inflamm Allergy Drug Discov (2010) 4:231-43. doi:10.2174/187221310793564182
15. Wang RF. Functional control of regulatory T cells and cancer immunotherapy. Semin Cancer Biol (2006) 16:106-14. doi:10.1016/j.semcancer.2005.11.004
16. Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol (2013) 25:469-84. doi:10.1016/j.smim.2013.10.008
17. Kaufmann SH, Lange C, Rao M, Balaji KN, Lotze M, Schito M, et al. Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review. Lancet Respir Med (2014) 2:301-20. doi:10.1016/S2213-2600(14)70033-5
18. Zumla A, Rao M, Dodoo E, Maeurer M. Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis. BMC Med (2016) 14:89. doi:10.1186/s12916-016-0635-1
19. Gupta A, Misra A, Deretic V. Targeted pulmonary delivery of inducers of host macrophage autophagy as a potential host-directed chemotherapy of tuberculosis. Adv Drug Deliv Rev (2016) 102:10-20. doi:10.1016/j.addr.2016.01.016
20. O'Connor G, Gleeson LE, Fagan-Murphy A, Cryan SA, O'Sullivan MP, Keane J. Sharpening nature's tools for efficient tuberculosis control: a review of the potential role and development of host-directed therapies and strategies for targeted respiratory delivery. Adv Drug Deliv Rev (2016) 102:33-54. doi:10.1016/j.addr.2016.04.024
21. Hunter RL. Pathology of post primary tuberculosis of the lung: an illustrated critical review. Tuberculosis (Edinb) (2011) 91:497-509. doi:10.1016/j.tube.2011.03.007
22. Hunter RL, Actor JK, Hwang SA, Karev V, Jagannath C. Pathogenesis of post primary tuberculosis: immunity and hypersensitivity in the development of cavities. Ann Clin Lab Sci (2014) 44:365-87.
23. Kim MJ, Wainwright HC, Locketz M, Bekker LG, Walther GB, Dittrich C, et al. Caseation of human tuberculosis granulomas correlates with elevated host lipid metabolism. EMBO Mol Med (2010) 2:258-74. doi:10.1002/emmm.201000079
24. Mitchison DA, Davies GR. Assessment of the efficacy of new anti-tuberculosis drugs. Open Infect Dis J (2008) 2:59-76. doi:10.2174/1874279300802010059
25. Hunter RL. Tuberculosis as a three-act play: a new paradigm for the pathogenesis of pulmonary tuberculosis. Tuberculosis (Edinb) (2016) 97:8-17. doi:10.1016/j.tube.2015.11.010
26. Heo EY, Chun EJ, Lee CH, Kim YW, Han SK, Shim YS, et al. Radiographic improvement and its predictors in patients with pulmonary tuberculosis. Int J Infect Dis (2009) 13:e371-6. doi:10.1016/j.ijid.2009.01.007
27. Janols H, Abate E, Idh J, Senbeto M, Britton S, Alemu S, et al. Early treatment response evaluated by a clinical scoring system correlates with the prognosis of pulmonary tuberculosis patients in Ethiopia: a prospective follow-up study. Scand J Infect Dis (2012) 44:828-34. doi:10.3109/00365548.2012.694468
28. Jayasankar K, Shakila H, Umapathy KC, Ramanathan VD. Biochemical and histochemical changes pertaining to active and healed cutaneous tuberculosis. Br J Dermatol (2002) 146:977-82. doi:10.1046/j.1365-2133.2002.04784.x
29. Kim CH, Choi KJ, Yoo SS, Lee SY, Won DI, Lim JO, et al. Comparative analysis of whole-blood interferon-gamma and flow cytometry assays for detecting post-treatment immune responses in patients with active tuberculosis. Cytometry B Clin Cytom (2014) 86:236-43. doi:10.1002/cyto.b.21110
30. Qian X, Nguyen DT, Li Y, Lyu J, Graviss EA, Hu TY. Predictive value of serum bradykinin and desArg9-bradykinin levels for chemotherapeutic responses in active tuberculosis patients: a retrospective case series. Tuberculosis (Edinb) (2016) 101:S109-18. doi:10.1016/j.tube.2016.09.022
31. Brown RE, Bostrom B, Zhang PL. Morphoproteomics and bortezomib/dexamethasone-induced response in relapsed acute lymphoblastic leukemia. Ann Clin Lab Sci (2004) 34:203-5.
32. Brown RE. Morphogenomics and morphoproteomics: a role for anatomic pathology in personalized medicine. Arch Pathol Lab Med (2009) 133:568-79. doi:10.1043/1543-2165-133.4.568
33. Alexandrescu S, Tatevian N, Czerniak BA, Covinsky MH, Burns NK, Brown RE. Morphoproteomics provides support for TGF-beta pathway signaling in the osteoclastogenesis and immune dysregulation of osteolytic Langerhans cell histiocytosis. Int J Clin Exp Pathol (2012) 5:503-11.
34. Brown RE, Buryanek J, Katz AM, Paz K, WolffJE. Alveolar rhabdomyosarcoma: morphoproteomics and personalized tumor graft testing further define the biology of PAX3-FKHR(FOXO1) subtype and provide targeted therapeutic options. Oncotarget (2016) 7:46263-72. doi:10.18632/oncotarget.10089
35. Brown RE, Buryanek J, Tammisetti VS, McGuire MF, Csencsits-Smith K. Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: pathogenesis. Oncotarget (2016) 7:41612-21. doi:10.18632/oncotarget.9508
36. Brown RE, Zhang PL, Lun M, Zhu S, Pellitteri PK, Riefkohl W, et al. Morphoproteomic and pharmacoproteomic rationale for mTOR effectors as therapeutic targets in head and neck squamous cell carcinoma. Ann Clin Lab Sci (2006) 36:273-82.
37. Brown RE, Zotalis G, Zhang PL, Zhao B. Morphoproteomic confirmation of a constitutively activated mTOR pathway in high grade prostatic intraepithelial neoplasia and prostate cancer. Int J Clin Exp Pathol (2008) 1:333-42.
38. Dhingra S, Rodriguez ME, Shen Q, Duan X, Stanton ML, Chen L, et al. Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications. Int J Clin Exp Pathol (2010) 4:134-46.
39. Liu J, Brown RE. Morphoproteomics demonstrates activation of mTOR pathway in anaplastic thyroid carcinoma: a preliminary observation. Ann Clin Lab Sci (2010) 40:211-7.
40. Liu J, Brown RE. Morphoproteomic confirmation of an activated nuclear factor-small ka, CyrillicBp65 pathway in follicular thyroid carcinoma. Int J Clin Exp Pathol (2012) 5:216-23.
41. Quesada AE, Assylbekova B, Jabcuga CE, Zhang R, Covinsky M, Rios A, et al. Expression of Sirt1 and FoxP3 in classical Hodgkin lymphoma and tumor infiltrating lymphocytes: implications for immune dysregulation, prognosis and potential therapeutic targeting. Int J Clin Exp Pathol (2015) 8:13241-8.
42. Quesada AE, Nguyen ND, Rios A, Brown RE. Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-kappaB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options. Int J Clin Exp Pathol (2014) 7:8732-9.
43. Shen Q, Stanton ML, Feng W, Rodriguez ME, Ramondetta L, Chen L, et al. Morphoproteomic analysis reveals an overexpressed and constitutively activated phospholipase D1-mTORC2 pathway in endometrial carcinoma. Int J Clin Exp Pathol (2010) 4:13-21.
44. Rios A, Hsu SH, Blanco A, Buryanek J, Day AL, McGuire MF, et al. Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100 (plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide. Oncoscience (2016) 3:156-63. doi:10.18632/oncoscience.311
45. Subbiah V, Wagner MJ, McGuire MF, Sarwari NM, Devarajan E, Lewis VO, et al. Personalized comprehensive molecular profiling of high risk osteosarcoma: implications and limitations for precision medicine. Oncotarget (2015) 6:40642-54. doi:10.18632/oncotarget.5841
46. WolffJE, Brown RE, Buryanek J, Pfister S, Vats TS, Rytting ME. Preliminary experience with personalized and targeted therapy for pediatric brain tumors. Pediatr Blood Cancer (2012) 59:27-33. doi:10.1002/pbc.23402
47. Lam KK, Zheng X, Forestieri R, Balgi AD, Nodwell M, Vollett S, et al. Nitazoxanide stimulates autophagy and inhibits mTORC1 signaling and intracellular proliferation of Mycobacterium tuberculosis. PLoS Pathog (2012) 8:e1002691. doi:10.1371/journal.ppat.1002691
48. Petruccioli E, Romagnoli A, Corazzari M, Coccia EM, Butera O, Delogu G, et al. Specific T cells restore the autophagic flux inhibited by Mycobacterium tuberculosis in human primary macrophages. J Infect Dis (2012) 205:1425-35. doi:10.1093/infdis/jis226
49. Gupta A, Pant G, Mitra K, Madan J, Chourasia MK, Misra A. Inhalable particles containing rapamycin for induction of autophagy in macrophages infected with Mycobacterium tuberculosis. Mol Pharm (2014) 11:1201-7. doi:10.1021/mp4006563
50. Schiebler M, Brown K, Hegyi K, Newton SM, Renna M, Hepburn L, et al. Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion. EMBO Mol Med (2014) 7:127-39. doi:10.15252/emmm.201404137
51. Zullo AJ, Lee S. Mycobacterial induction of autophagy varies by species and occurs independently of mammalian target of rapamycin inhibition. J Biol Chem (2012) 287:12668-78. doi:10.1074/jbc. M111.320135
52. Jagannath C, Bakhru P. Rapamycin-induced enhancement of vaccine efficacy in mice. Methods Mol Biol (2012) 821:295-303. doi:10.1007/978-1-61779-430-8_18
53. Jagannath C, Lindsey DR, Dhandayuthapani S, Xu Y, Hunter RL Jr, Eissa NT. Autophagy enhances the efficacy of BCG vaccine by increasing peptide presentation in mouse dendritic cells. Nat Med (2009) 15:267-76. doi:10.1038/nm.1928
54. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H, et al. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol (2004) 166:213-23. doi:10.1083/jcb.200403069
55. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science (2011) 332:1317-22. doi:10.1126/science.1199498
56. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, Villen J, et al. Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science (2011) 332:1322-6. doi:10.1126/science.1199484
57. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, et al. PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 117:730-8. doi:10.1172/JCI28984
58. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 307:1098-101. doi:10.1126/science.1106148
59. Nishimura T, Zhao X, Gan H, Koyasu S, Remold HG. The prostaglandin E2 receptor EP4 is integral to a positive feedback loop for prostaglandin E2 production in human macrophages infected with Mycobacterium tuberculosis. FASEB J (2013) 27:3827-36. doi:10.1096/fj.13-228858
60. Assis PA, Espindola MS, Paula-Silva FW, Rios WM, Pereira PA, Leao SC, et al. Mycobacterium tuberculosis expressing phospholipase C subverts PGE2 synthesis and induces necrosis in alveolar macrophages. BMC Microbiol (2014) 14:128. doi:10.1186/1471-2180-14-128
61. Whiteside TL. Disarming suppressor cells to improve immunotherapy. Cancer Immunol Immunother (2012) 61:283-8. doi:10.1007/s00262-011-1171-7
62. Welsh KJ, Risin SA, Actor JK, Hunter RL. Immunopathology of postprimary tuberculosis: increased T-regulatory cells and DEC-205-positive foamy macrophages in cavitary lesions. Clin Dev Immunol (2011) 2011:307631. doi:10.1155/2011/307631
63. Rangel Moreno J, Estrada Garcia I, De La Luz Garcia Hernandez M, Aguilar Leon D, Marquez R, Hernandez Pando R. The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. Immunology (2002) 106:257-66. doi:10.1046/j.1365-2567.2002.01403.x
64. Jang TJ. Progressive increase of regulatory T cells and decrease of CD8+ T cells and CD8+ T cells/regulatory T cells ratio during colorectal cancer development. Korean J Pathol (2013) 47:443-51. doi:10.4132/KoreanJPathol.2013.47.5.443
65. McNab FW, Berry MP, Graham CM, Bloch SA, Oni T, Wilkinson KA, et al. Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients with active tuberculosis. Eur J Immunol (2011) 41:1941-7. doi:10.1002/eji.201141421
66. Trinath J, Maddur MS, Kaveri SV, Balaji KN, Bayry J. Mycobacterium tuberculosis promotes regulatory T-cell expansion via induction of programmed death-1 ligand 1 (PD-L1, CD274) on dendritic cells. J Infect Dis (2012) 205:694-6. doi:10.1093/infdis/jir820
67. Jurado JO, Alvarez B, Pasquinelli V, Martinez GJ, Quiroga MF, Abbate E, et al. Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J Immunol (2008) 181:116-25. doi:10.4049/jimmunol.181.1.116
68. Sakhno LV, Tikhonova MA, Tyrinova TV, Leplina OY, Shevela EY, Nikonov SD, et al. Cytotoxic activity of dendritic cells as a possible mechanism of negative regulation of T lymphocytes in pulmonary tuberculosis. Clin Dev Immunol (2012) 2012:628635. doi:10.1155/2012/628635
69. Singh A, Dey AB, Mohan A, Sharma PK, Mitra DK. Foxp3+ regulatory T cells among tuberculosis patients: impact on prognosis and restoration of antigen specific IFN-gamma producing T cells. PLoS One (2012) 7:e44728. doi:10.1371/journal.pone.0044728
70. Singh A, Mohan A, Dey AB, Mitra DK. Inhibiting the programmed death 1 pathway rescues Mycobacterium tuberculosis-specific interferon gamma-producing T cells from apoptosis in patients with pulmonary tuberculosis. J Infect Dis (2013) 208:603-15. doi:10.1093/infdis/jit206
71. Liu Y, Yang F, Ma W, Sun Q. Metformin inhibits proliferation and proinflammatory cytokines of human keratinocytes in vitro via mTOR-signaling pathway. Pharm Biol (2015) 54(7):1173-8. doi:10.1016/j.jpba.2014.11.001
72. Singhal A, Jie L, Kumar P, Hong GS, Leow MK, Paleja B, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med (2014) 6:263ra159. doi:10.1126/scitranslmed.3009885
73. Jendrossek V. Targeting apoptosis pathways by Celecoxib in cancer. Cancer Lett (2013) 332:313-24. doi:10.1016/j.canlet.2011.01.012
74. Ganbat D, Seehase S, Richter E, Vollmer E, Reiling N, Fellenberg K, et al. Mycobacteria infect different cell types in the human lung and cause species dependent cellular changes in infected cells. BMC Pulm Med (2016) 16:19. doi:10.1186/s12890-016-0185-5
75. HarriffMJ, Cansler ME, Toren KG, Canfield ET, Kwak S, Gold MC, et al. Human lung epithelial cells contain Mycobacterium tuberculosis in a late endosomal vacuole and are efficiently recognized by CD8(+) T cells. PLoS One (2014) 9:e97515. doi:10.1371/journal.pone.0097515
76. Mustafa T, Leversen NA, Sviland L, Wiker HG. Differential in vivo expression of mycobacterial antigens in Mycobacterium tuberculosis infected lungs and lymph node tissues. BMC Infect Dis (2014) 14:535. doi:10.1186/1471-2334-14-535
77. Purohit MR, Sviland L, Wiker H, Mustafa T. Rapid and specific diagnosis of extrapulmonary tuberculosis by immunostaining of tissues and aspirates with anti-MPT64. Appl Immunohistochem Mol Morphol (2016). doi:10.1097/PAI.0000000000000300
78. Mahon RN, Hafner R. Immune cell regulatory pathways unexplored as host-directed therapeutic targets for Mycobacterium tuberculosis: an opportunity to apply precision medicine innovations to infectious diseases. Clin Infect Dis (2015) 61(Suppl 3):S200-16. doi:10.1093/cid/civ621